Loading
India has shown CAR-T can be made for a tenth of the US price. Public production in large middle-income countries could make it available to millions who are currently excluded.
NexCAR19 (ImmunoACT, Tata Memorial and IIT Bombay) was approved in India in 2023 at around $40,000; Brazil's Fiocruz and Butantan and China's academic centres are building comparable capacity. The proposal is a coordinated public-sector programme in three to five large middle-income countries with shared vector supply, shared training, a common product dossier adapted for national regulators, and outcome registries, aimed at treating relapsed B-cell malignancies at under $50,000 per dose within public health systems.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, CAR-T cell therapy.
Shares Talicabtagene autoleucel, Tata Memorial Centre, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.